AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial
#3PRI RANKED
Most Cited Paper
in Virus-based gene therapy research
18 Months Post-Publication
Class of 2026
“AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/virus-based-gene-therapy-research/2026/
Topics
Duchenne Muscular Dystrophy · DMD gene · Dystrophin · Delandistrogene moxeparvovec · adeno-associated rh74 viral vector · AAV Gene Therapy · micro-dystrophin expression · North Star Ambulatory Assessment · North Star Ambulatory Assessment · Time to Rise · 10-meter Walk/Run · stride velocity 95th centile · 100-meter Walk/Run · 4-step ascent · PROMIS Mobility · Upper Extremity · ambulatory males · Intravenous Administration · Genome Copies Per Kilogram
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Virus-based gene therapy research Papers, Class of 2026. https://pri.pepkio.com/top-papers/virus-based-gene-therapy-research/2026. Accessed 2026-07-20. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459